Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays

BACKGROUND: The commercialization of CT-P13, an infliximab (IFX) biosimilar, has the potential to decrease health-related costs and enhance access to biological therapies. This study aimed to address the accuracy and inter-assay agreement of the CT-P13 quantification using four different assays init...

Descripción completa

Detalles Bibliográficos
Autores principales: Afonso, Joana, de Sousa, Helena Tavares, Rosa, Isadora, Carvalho, João, Dias, Cláudia Camila, Magro, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598811/
https://www.ncbi.nlm.nih.gov/pubmed/28932268
http://dx.doi.org/10.1177/1756283X17722915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598811/
https://www.ncbi.nlm.nih.gov/pubmed/28932268
http://dx.doi.org/10.1177/1756283X17722915

Ejemplares similares